Previous Close | 0.7708 |
Open | 0.7560 |
Bid | 0.7708 x 0 |
Ask | 0.8014 x 0 |
Day's Range | 0.7560 - 0.7706 |
52 Week Range | 0.6435 - 4.1040 |
Volume | |
Avg. Volume | 412 |
Market Cap | 53.737M |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0240 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.86 |
-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION remains on track with 16-week results expected in Q4 2022- -As of March 31, 2022, UNITY had approximately $79.2 million in cash, cash equivalents and marketable securities, extending runway through Q1 2023-
Cellular senescence biology in eye disease was a focal point at ARVO opening symposiumSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting featuring UBX1325 as a potential treatment for diabetic macular edema (DME) and wet age-related m
SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meetin